COX and cancer

QJM: An International Journal of Medicine

Volumn 98, Issue 10, 2005, Pages 711-718

  Mazhar, D ^a   Gillmore, R ^a   Waxman, J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; INDOMETACIN; IRINOTECAN; ISOENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; VALDECOXIB; VINBLASTINE;

ANALGESIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN HEMORRHAGE; CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; ENZYME INDUCTION; GASTROINTESTINAL HEMORRHAGE; GENE OVEREXPRESSION; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOSIS; XENOBIOTIC METABOLISM;

EID: 27644539409     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci119     Document Type: Review

References (77)

1. Maekawa M, Sugano K, Sano H, et al. Increased expression of cyclo-oxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 1998; 28:421-6.
2. Gupta S, Srivastava M, Ahmad N, et al. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42:73-8.
3. Parrett ML, Harris RE, Joarder FS, et al. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997; 10:503-7.
4. Gasparini G, Longo R, Sarmiento R, et al. Inhibitors of cyclooxygenase 2: A new class of anticancer agents? Lancet Oncol 2003; 4:605-15.
5. Koki AT, Masterrer JL. Celeroxib: A specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9:28-35.
6. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56:4424-9.
7. Gilhooly EM, Rose DP. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 1999; 15:267-70.
8. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular and molecular biology. Annu Rev Biochem 2000; 69:145-82.
9. Subbaramaiah K, Altorki N, Chung WJ, et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274:10911-15.
10. Leung WK, To KF, Ng YP, et al. Association between cyclooygenase 2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001; 84:335-9.
11. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62:632-5.
12. Song SH, Jong HS, Choi HH, et al. Transcriptional silencing of cyclooxygenase-2 by hypermethylation of the 5′CpG island in human gastric carcinoma cells. Cancer Res 201; 61:4628-35.
13. Williams CS, Luongo C, Radnika A, et al. Elevated cyclo-oxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111:1134-40.
14. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc A716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87:803-9.
15. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase (COX)-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276:18563-9.
16. Neufang G, Furstenberger G, Heidt M, et al. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA 2001; 98:7629-34.
17. Thun MJ, Henley SJ, Patron OC. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 99:13926-31.
18. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of breast cancer in rats by celecoxib - a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60:293-7.
19. Alshafie GA, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000; 7:1377-81.
20. Williams CS, Watson AJ, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60:6045-51.
21. Nishimura G, Yanoma S, Mizuno H, et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999; 90:1152-62.
22. Tomozawa S, Nagawa H, Tsuno N, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999; 81:1274-9.
23. Milas L, Kishi K, Hunter N, et al. Enhancement of tumour response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999; 91:1501-4.
24. Hilda T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 2002; 8:2443-7.
25. Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute Workshop on chemopreventive properties of non-steroidal anti-inflammatory drugs: role of COX-dependent and independent mechanisms. Neoplasia 2002; 4:91-7.
26. Elder DJ, Hague A, Hicks DJ, et al. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumour cell lines; enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996; 56:2273.
27. Shift SJ, Qigo L, Jsgi LL, et al. Sulindac sulphide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96:491.
28. Samaha HS, Kellott, GJ, Steele V, et al. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcatteate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57:1301.
29. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apopotosis in familial adenomatous polyposis. Gastroenterology 1995; 109:994.
30. Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-KB pathway. J Biol Chem 1999; 274:27307-14.
31. Zhang L, Yu J, Park BH, et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290:989-92.
32. Tsujii M, Kawamo S, Tsujii S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-16.
33. Leahy KM, Ornberg RL, Wang Y, et al. Cyclo-oxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62:625-31.
34. Uefuji K, Ichikura T, Mochizuki H. Cyclo-oxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6:135-8.
35. Masferrer JL, Lehy KM, Koki AT, et al. Anti-angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-11.
36. Dormond O, Foletti A, Paroz C, et al. NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nature Med 2001; 7:1041-7.
37. Plastaras JP, Guengerich FP, Nebert DW, et al. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem 2000; 275:11784-90.
38. Tsujii M, Kawano S and Dubois RN. Cyclo-oxygenase-2 expression in human colon cancer cells increases metastatic potential. PNAS 1997; 94:3336-40.
39. Dohadwala M, Luo J, Zhu,L, et al. Non-small cell lung cancer cyclooxygenase-2 dependent invasion is mediated by CD44. J Biol Chem 2001; 276:20809-12.
40. Yao M, Kargman S, Lam FC, et al. Inhibition of cyclooxygenase-2 by rofe coxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2002; 62:1567-72.
41. Harris RE, Robertson FM, Abou-Issa JM, et al. Genetic induction and up-regulation of cyclooxygenase (COX) and aromatase (CYP 19): An extension of the dietary fat hypothesis in breast cancer. Med Hypotheses 1999; 52:291-2.
42. Brueggemeier RW, Quinn AL, Parrett ML, et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140:27-35.
43. Bennett A, Gaffen JD, Melhuish PB, Stamford IF. Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate. Br J Pharmacol 1987; 91:229-35.
44. Cassidy PB, Moos PJ, Kelly RC, Fitzpatrick FA. Cyclooxygenase-2 induction by paclitaxel, docetaxel and taxane analogues in human monocytes and murine macrophages: Structure-activity relationships and their implications. Clin Cancer Res 2002; 8:846-55.
45. Soriano AF, Helfrich B, Chan DC, Heasley LF, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999; 59:6178-84.
46. Tritan OC, Durham WF, Salatar VS, et al. COX-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhoea side effect of CPT-11. Cancer Res 2002; 62:5778-84.
47. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionising radiation. Am J Clin Oncol 2001; 24:438-42.
48. Pesenti E, Masterrer JL, Di Salle E. Effect of exemestane and celecoxib alone or in combination on the DMBA-induced mammary carcinoma in rats. Breast Cancer Res Treat 2001; 69:288 (abstr 445).
49. Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003; 9:1566-72.
50. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Increased expression of cyclooxygenase-2 in HER-2 over-expressing human breast cancer cells. NCI 7th SPORE Investigators' Workshop, 1999.
51. Mann M, Sheng H, Shao J, et al. Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120:1713-19.
52. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Eng J Med 1991; 325:1593-6.
53. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53:1322-7.
54. Paganini-Hill A. Aspirin and colorectal cancer. The leisure world cohort revisited. Prev Med 1995; 24:113.
55. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Eng J Med 1995; 333:609.
56. Thun MJ, Heath CW. Aspirin use and reduced risk of gastrointestinal tract cancers in the American Cancer Society prospective studies. Prev Med 1995; 24:116.
57. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: Effects of dosage and timing. Br J Cancer 1999; 81:62.
58. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin non steroidal anti inflammatory drugs. Epidemiology 2001; 12:88-93.
59. Gridley G, McLaughlin JK, Ekbom A. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307.
60. Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994; 5:138.
61. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukaemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31:691.
62. Johnson TW, Anderson KE, Lazovich D, Folson AR. Association of aspirin and non-steroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1586-91.
63. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: Prospective results from the Women's Health Initiative. Cancer Res 2003; 63:6096-101.
64. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77:511-15.
65. Leitzmann MF, Stampfer MJ, Ma J, et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:1108-11.
66. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDS): Results of a case-control study. Oncol Rep 2000; 7:169-70.
67. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77:219-25.
68. Moysich KB, Menezes RJ, Ronsani A, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002; 2:31.
69. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Eng J Med 1989; 321:129.
70. Giardiello FM, Hamilton SR, Krusen AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med 193; 328:1313-16.
71. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med 2000; 342:1946-52.
72. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54:5602-6.
73. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capacitabine-induced hand-and-foot syndrome and antitumor activity. Oncology 2002; 16 (Suppl. 14):31-7.
74. Bombardier C, Laine L, Reicin A, et al. Group comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 2000; 343:1520-8.
75. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteo arthritis aAd rheumatoid arthritis: The CLASS study: a randomized controlled trial. JAMA 2000; 284:1247-55.
76. Merck announces voluntary withdrawal of VIOXX. News Release. Whitehouse Station NJ, Merck. 2004. [www.vioxx.com/vioxx/documents/english/ vioxx_press_release.pdf]
77. DeMaria AN, Weir MR. Coxibs - beyond the GI tract: Renal and cardiovascular issues. J Pain Symptom Manage 2003; 25 (Suppl. 2):S41-9.